TABLE 2.
THE COLISTIN EFFICACY
| References | Report features
|
||||
|---|---|---|---|---|---|
| Number of patiens | Conditions treated | Pathogen | Therapy | % success | |
| Reina (40) | 55 | VAP+ other infection | P. aeruginosa (35%) A. Baumanii (65%) |
5 mg/kg per day divided into three doses iv | 66% |
| Levin (38) | 59 | Pneumonia + other infection | P. aeruginosa (35%) A. baumanii (65%) |
6,67–13,3mg/Kg per day divided into three doses iv | 58% (25% for pneumonia) |
| Garnacho_ (39) | 21 | VAP | P. aeruginosa (35%) A. baumanii (65%) |
2,5–5mg/kg every 8h iv | 57% |
| Kwa (41) | 21 | Pneumonia (3VAP) | P. aeruginosa (19%) A. baumanii (81%) |
1 million units of inhaled Colistin every 8h+other antimicrobials iv | 85,7% |
| Michalopoulos (43) | 8 | VAP | P. aeruginosa (13%) A. baumanii (87%) |
0,5–2million units of inhaled Colistin every 8h+2million units Colistin every 8h o other antimicrobials iv | 88% |
| Michalopoulos (44) | 60 | VAP | P. aeruginosa (20%) A. baumanii (62%) K. pneumoniae (18%) |
2.2(±0.7) million international units of inhaled Colistin + Colistin o other antimicrobials iv | 83% |